Winnipeg Rh Institute Foundation Inc. Report issue

Foundation Phase 2

Organization Overview

First Clinical Trial
2019
NCT04019106
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Winnipeg Rh Institute Foundation Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

budesonide (rhinocort) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bronchopulmonary Dysplasia (Phase 2)

Respiratory Distress Syndrome (Phase 2)

Respiratory Distress Syndrome, Newborn (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1